

Shinkyu Yoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1218070/publications.pdf>

Version: 2024-02-01

52
papers

567
citations

759233

12
h-index

713466

21
g-index

55
all docs

55
docs citations

55
times ranked

968
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 297, 87-96.	7.3	70
2	Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation. <i>Cancer Research</i> , 2018, 78, 4482-4496.	0.9	53
3	Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e211136.	5.9	43
4	Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 1549-1556.	3.0	36
5	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016, 7, 76934-76943.	1.8	33
6	Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection. <i>Clinical Lung Cancer</i> , 2015, 16, e203-e212.	2.6	27
7	Pneumatosis Intestinalis After Cetuximab-containing Chemotherapy for Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1225-1228.	1.3	23
8	Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Oncolmunology</i> , 2020, 9, 1776058.	4.6	19
9	Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 120.	3.7	18
10	Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. <i>Translational Oncology</i> , 2019, 12, 852-858.	3.7	14
11	Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3025-3036.	2.5	14
12	Blood Vessel Invasion Predicts Postoperative Survival Outcomes and Systemic Recurrence Regardless of Location or Blood Vessel Type in Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7279-7290.	1.5	14
13	HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. <i>BMB Reports</i> , 2018, 51, 660-665.	2.4	14
14	The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205. <i>American Journal of Cancer Research</i> , 2019, 9, 597-607.	1.4	14
15	CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 449-458.	4.4	13
16	Real-world data analysis of patients with cancer of unknown primary. <i>Scientific Reports</i> , 2021, 11, 23074.	3.3	13
17	Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 2551-2561.	2.8	12
18	Relevance of prognostic index with β 2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era. <i>Blood Research</i> , 2017, 52, 276.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center. <i>PLoS ONE</i> , 2019, 14, e0221065.	2.5	11
20	Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 3197-3204.	2.8	10
21	Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients. <i>Journal of Korean Medical Science</i> , 2013, 28, 1248.	2.5	9
22	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). <i>European Journal of Cancer</i> , 2020, 127, 183-190.	2.8	9
23	Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis. <i>PLoS ONE</i> , 2020, 15, e0231546.	2.5	9
24	Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 148, 202-210.	2.8	9
25	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. <i>Cancer Research and Treatment</i> , 2022, 54, 1-9.	3.0	9
26	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.	1.1	9
27	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIb-IV gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 182-189.	5.3	6
28	<p>Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6045-6052.	2.0	6
29	Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 2878-2894.	1.4	6
30	Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients. <i>Annals of Laboratory Medicine</i> , 2021, 41, 207-213.	2.5	5
31	Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 19596.	3.3	5
32	A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. <i>Investigational New Drugs</i> , 2019, 37, 1239-1246.	2.6	4
33	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1897-1905.	2.5	4
34	Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. <i>BMC Cancer</i> , 2021, 21, 731.	2.6	4
35	The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery. <i>Cancer Research and Treatment</i> , 2022, 54, 226-233.	3.0	2
36	Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations. <i>American Journal of Cancer Research</i> , 2019, 9, 1708-1721.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Primary hepatic mixed germ cell tumor in an adult. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 355-359.	1.1	1
38	Integrin $\alpha 3$ Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	1
39	Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4534-4534.	1.6	1
40	The different path of T790M-positive EGFR-mutant lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, S47-S47.	1.7	1
41	Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Annals of Translational Medicine</i> , 2017, 5, 11-11.	1.7	1
42	Osimertinib, the winner, but cannot yet take it all. <i>Annals of Translational Medicine</i> , 2018, 6, 61-61.	1.7	1
43	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	2.8	1
44	Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). <i>Journal of Thoracic Disease</i> , 2017, 9, 3525-3528.	1.4	0
45	ASO Visual Abstract: Blood Vessel Invasion Predicts Postoperative Survival Outcomes and Systemic Recurrence Regardless of Location or Blood Vessel Type in Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 496-496.	1.5	0
46	Comparison of Survival and Clinical Features In Different Age Cohorts of Patients with Multiple Myeloma: A Single Center Experience. <i>Blood</i> , 2010, 116, 4997-4997.	1.4	0
47	A phase I dose escalation study to evaluate safety and tolerability of cabazitaxel (Cbz) as a single agent in patients (pts) with advanced gastric adenocarcinoma who have failed prior chemotherapy (CT) regimens (GASTANA).. <i>Journal of Clinical Oncology</i> , 2014, 32, 141-141.	1.6	0
48	Proposal of New Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2014, 124, 1668-1668.	1.4	0
49	The role of FDG-PET during osimertinib treatment to predict the responsiveness of tumor early in patients with stage IV non-small cell lung cancer: A pilot study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21150-e21150.	1.6	0
50	Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 355-355.	1.6	0
51	A prospective phase II trial of gemcitabine plus axitinib in patients with sarcomatoid type renal carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 616-616.	1.6	0
52	Identifying mechanisms of acquired immune escape from sequential, paired biopsies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2519-2519.	1.6	0